132 related articles for article (PubMed ID: 30040896)
1. Surface Probing by Fragment-Based Screening and Computational Methods Identifies Ligandable Pockets on the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Lucas X; Van Molle I; Ciulli A
J Med Chem; 2018 Aug; 61(16):7387-7393. PubMed ID: 30040896
[TBL] [Abstract][Full Text] [Related]
2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
3. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders.
Diehl CJ; Ciulli A
Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982
[TBL] [Abstract][Full Text] [Related]
4. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
5. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A
Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187
[TBL] [Abstract][Full Text] [Related]
6. Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers.
Vu LP; Diehl CJ; Casement R; Bond AG; Steinebach C; Strašek N; Bricelj A; Perdih A; Schnakenburg G; Sosič I; Ciulli A; Gütschow M
J Med Chem; 2023 Sep; 66(18):12776-12811. PubMed ID: 37708384
[TBL] [Abstract][Full Text] [Related]
7. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
8. DNA-encoded library-enabled discovery of proximity-inducing small molecules.
Mason JW; Chow YT; Hudson L; Tutter A; Michaud G; Westphal MV; Shu W; Ma X; Tan ZY; Coley CW; Clemons PA; Bonazzi S; Berst F; Briner K; Liu S; Zécri FJ; Schreiber SL
Nat Chem Biol; 2024 Feb; 20(2):170-179. PubMed ID: 37919549
[TBL] [Abstract][Full Text] [Related]
9. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
[TBL] [Abstract][Full Text] [Related]
10. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
[TBL] [Abstract][Full Text] [Related]
11. Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia.
Russell RC; Sufan RI; Zhou B; Heir P; Bunda S; Sybingco SS; Greer SN; Roche O; Heathcote SA; Chow VW; Boba LM; Richmond TD; Hickey MM; Barber DL; Cheresh DA; Simon MC; Irwin MS; Kim WY; Ohh M
Nat Med; 2011 Jun; 17(7):845-53. PubMed ID: 21685897
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibitors of the interaction between the E3 ligase VHL and HIF1α.
Buckley DL; Gustafson JL; Van Molle I; Roth AG; Tae HS; Gareiss PC; Jorgensen WL; Ciulli A; Crews CM
Angew Chem Int Ed Engl; 2012 Nov; 51(46):11463-7. PubMed ID: 23065727
[TBL] [Abstract][Full Text] [Related]
13. Development of VHL-recruiting STING PROTACs that suppress innate immunity.
Zhu Z; Johnson RL; Zhang Z; Herring LE; Jiang G; Damania B; James LI; Liu P
Cell Mol Life Sci; 2023 May; 80(6):149. PubMed ID: 37183204
[TBL] [Abstract][Full Text] [Related]
14. Development of visible-light-activatable photocaged PROTACs.
Weng W; Xue G; Pan Z
Eur J Med Chem; 2024 Feb; 265():116062. PubMed ID: 38128235
[TBL] [Abstract][Full Text] [Related]
15. Ternary Complex-Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo-PROTACs.
Diehl CJ; Salerno A; Ciulli A
Angew Chem Int Ed Engl; 2024 Jun; 63(25):e202319456. PubMed ID: 38626385
[TBL] [Abstract][Full Text] [Related]
16. Preparation of von Hippel-Lindau (VHL) E3 ubiquitin ligase ligands exploiting constitutive hydroxyproline for benzylic amine protection.
Soto-Martínez DM; Clements GD; Díaz JE; Becher J; Reynolds RC; Ochsenbauer C; Snowden TS
RSC Adv; 2024 May; 14(24):17077-17090. PubMed ID: 38808246
[TBL] [Abstract][Full Text] [Related]
17. Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability.
Wu H; Murray J; Ishisoko N; Frommlet A; Deshmukh G; DiPasquale A; Mulvihill MM; Zhang D; Quinn JG; Blake RA; Fairbrother WJ; Fuhrmann J
J Med Chem; 2024 Jun; 67(11):8585-8608. PubMed ID: 38809766
[TBL] [Abstract][Full Text] [Related]
18. Proteome-scale discovery of protein degradation and stabilization effectors.
Poirson J; Cho H; Dhillon A; Haider S; Imrit AZ; Lam MHY; Alerasool N; Lacoste J; Mizan L; Wong C; Gingras AC; Schramek D; Taipale M
Nature; 2024 Apr; 628(8009):878-886. PubMed ID: 38509365
[TBL] [Abstract][Full Text] [Related]
19. Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells.
Offensperger F; Tin G; Duran-Frigola M; Hahn E; Dobner S; Ende CWA; Strohbach JW; Rukavina A; Brennsteiner V; Ogilvie K; Marella N; Kladnik K; Ciuffa R; Majmudar JD; Field SD; Bensimon A; Ferrari L; Ferrada E; Ng A; Zhang Z; Degliesposti G; Boeszoermenyi A; Martens S; Stanton R; Müller AC; Hannich JT; Hepworth D; Superti-Furga G; Kubicek S; Schenone M; Winter GE
Science; 2024 Apr; 384(6694):eadk5864. PubMed ID: 38662832
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore-Based Machine Learning Model To Predict Ligand Selectivity for E3 Ligase Binders.
Karki R; Gadiya Y; Gribbon P; Zaliani A
ACS Omega; 2023 Aug; 8(33):30177-30185. PubMed ID: 37636935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
